European Medicines Agency decision
P/0214/2015

of 2 October 2015


Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.
European Medicines Agency decision
P/0214/2015

of 2 October 2015


The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,


Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency2,

Having regard to the European Medicines Agency’s decision P/0091/2012 issued on 29 May 2012,

Having regard to the application submitted by Baxalta Innovations GmbH on 20 May 2015 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 14 August 2015, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

Has adopted this decision:

**Article 1**

Changes to the agreed paediatric investigation plan for vonicog alfa, powder and solvent for solution for injection, intravenous use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

**Article 2**

This decision is addressed to Baxalta Innovations GmbH, Industriestrasse 67, 1221 - Vienna, Austria.

Done at London, 2 October 2015

For the European Medicines Agency
Jordi Llinares Garcia
Head of Division (ad interim)
Human Medicines Research and Development Support
(Signature on file)
Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan
EMEA-001164-PIP01-11-M01

Scope of the application

Active substance(s):
Vonicog alfa

Condition(s):
Treatment of von Willebrand Disease

Pharmaceutical form(s):
Powder and solvent for solution for injection

Route(s) of administration:
Intravenous use

Name/corporate name of the PIP applicant:
Baxalta Innovations GmbH

Basis for opinion


The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 16 June 2015.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.
Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.
Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)
1. Waiver

Not applicable.

2. Paediatric Investigation Plan

2.1. Condition

Treatment of von Willebrand Disease (VWD)

2.1.1. Indication(s) targeted by the PIP

Prevention and treatment of bleeding episodes and for surgical and invasive procedures in paediatric patients (less than 18 years of age) with von Willebrand disease

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Powder and solvent for solution for injection.

2.1.4. Measures

<table>
<thead>
<tr>
<th>Area</th>
<th>Number of studies</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quality-related studies</td>
<td>0</td>
<td>Not applicable.</td>
</tr>
<tr>
<td>Non-clinical studies</td>
<td>0</td>
<td>Not applicable.</td>
</tr>
<tr>
<td>Clinical studies</td>
<td>1</td>
<td><strong>Study 1</strong>: Open-label study to assess the safety and efficacy of rhVWF with or without ADVATE in the treatment and prevention of bleeding episodes in children diagnosed with severe hereditary VWD and to determine the pharmacokinetics (PK) of rhVWF.</td>
</tr>
<tr>
<td>Extrapolation, modelling and simulation studies</td>
<td>0</td>
<td>Not applicable.</td>
</tr>
<tr>
<td>Other studies</td>
<td>0</td>
<td>Not applicable.</td>
</tr>
<tr>
<td>Other measures</td>
<td>0</td>
<td>Not applicable.</td>
</tr>
</tbody>
</table>
3. Follow-up, completion and deferral of PIP

<table>
<thead>
<tr>
<th>Concerns on potential long term safety and efficacy issues in relation to paediatric use:</th>
<th>Yes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date of completion of the paediatric investigation plan:</td>
<td>By March 2019</td>
</tr>
<tr>
<td>Deferral for one or more studies contained in the paediatric investigation plan:</td>
<td>Yes</td>
</tr>
</tbody>
</table>